Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3202)
All Articles published online
|
Oct 21, 2008 (publication date) through Dec 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Moeser AJ, Nighot PK, Roerig B, Ueno R, Blikslager AT. Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 2008; 14(39): 6012-6017 [PMID: 18932279 DOI: 10.3748/wjg.14.6012] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i39/6012.htm |
| Number | Citing Articles |
| 1 |
Younggeon Jin, Anthony T Blikslager. ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target. Tissue Barriers 2015; 3(4): e1105906 doi: 10.1080/21688370.2015.1105906
|
| 2 |
Birgit Adam, Tobias Liebregts, Guido Gerken. Neue Medikamente zur Behandlung der Obstipation. Medizinische Klinik 2010; 105(7): 475 doi: 10.1007/s00063-010-1081-z
|
| 3 |
Ryota Ikee, Kazuhiro Yano, Tomomi Tsuru. Constipation in chronic kidney disease: it is time to reconsider. Renal Replacement Therapy 2019; 5(1) doi: 10.1186/s41100-019-0246-3
|
| 4 |
Young Su Park, Sang Bum Kang, Ronald R. Marchelletta, Harrison M. Penrose, Roos Ruiter-Visser, Barbara Jung, Michael J. Docherty, Brigid S. Boland, William J. Sandborn, Declan F. McCole. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients. Pharmaceutics 2023; 15(3): 811 doi: 10.3390/pharmaceutics15030811
|
| 5 |
Satish S.C. Rao, Peter Lichtlen, Sepideh Habibi. Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation. Journal of Clinical Gastroenterology 2021; 55(6): 512 doi: 10.1097/MCG.0000000000001385
|
| 6 |
Chander Shekhar, Peter J Whorwell. Emerging drugs for irritable bowel syndrome. Expert Opinion on Emerging Drugs 2009; 14(4): 673 doi: 10.1517/14728210903222279
|
| 7 |
Eikan Mishima, Shinji Fukuda, Hisato Shima, Akiyoshi Hirayama, Yasutoshi Akiyama, Yoichi Takeuchi, Noriko N. Fukuda, Takehiro Suzuki, Chitose Suzuki, Akinori Yuri, Koichi Kikuchi, Yoshihisa Tomioka, Sadayoshi Ito, Tomoyoshi Soga, Takaaki Abe. Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD. Journal of the American Society of Nephrology 2015; 26(8): 1787 doi: 10.1681/ASN.2014060530
|
| 8 |
Vesta Valuckaite, Olga Zaborina, Jason Long, Martin Hauer-Jensen, Junru Wang, Christopher Holbrook, Alexander Zaborin, Kenneth Drabik, Mukta Katdare, Helena Mauceri, Ralph Weichselbaum, Millicent A. Firestone, Ka Yee Lee, Eugene B. Chang, Jeffrey Matthews, John C. Alverdy. Oral PEG 15–20 protects the intestine against radiation: role of lipid rafts. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009; 297(6): G1041 doi: 10.1152/ajpgi.00328.2009
|
| 9 |
Sherman M Chamberlain, Satish SC Rao. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opinion on Drug Safety 2012; 11(5): 841 doi: 10.1517/14740338.2012.708732
|
| 10 |
Erick R Singh, Sherman M Chamberlain, Satish SC Rao. Constipation: Current & Emerging Treatments. 2013; : 118 doi: 10.2217/ebo.12.470
|
| 11 |
Galliano Zanello, Mustapha Berri, Joëlle Dupont, Pierre-Yves Sizaret, Romain D'Inca, Henri Salmon, François Meurens, David Ojcius. Saccharomyces cerevisiae Modulates Immune Gene Expressions and Inhibits ETEC-Mediated ERK1/2 and p38 Signaling Pathways in Intestinal Epithelial Cells. PLoS ONE 2011; 6(4): e18573 doi: 10.1371/journal.pone.0018573
|
| 12 |
John Cuppoletti, Anthony T Blikslager, Jayati Chakrabarti, Prashant K Nighot, Danuta H Malinowska. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacology 2012; 12(1) doi: 10.1186/1471-2210-12-3
|
| 13 |
Sang Bum Kang, Ronald R. Marchelletta, Harrison Penrose, Michael J. Docherty, Declan F. McCole. A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa. Pharmacology Research & Perspectives 2015; 3(2) doi: 10.1002/prp2.128
|
| 14 |
Kentaro Arakawa, Tomoaki Ishigami, Michiko Nakai-Sugiyama, Lin Chen, Hiroshi Doi, Tabito Kino, Shintaro Minegishi, Sae Saigoh-Teranaka, Rie Sasaki-Nakashima, Kiyoshi Hibi, Kazuo Kimura, Kouichi Tamura, Michael Bader. Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLOS ONE 2019; 14(6): e0218096 doi: 10.1371/journal.pone.0218096
|
| 15 |
Zahra Tofighi, Motahareh Golabi, Tayebeh Toliyat, Mohsen Naseri, Narguess Yassa. Formulation and Evaluation of an Iranian Traditional Dosage Form Containing Linum and Ficus for Improvement of Functional Constipation. Jundishapur Journal of Natural Pharmaceutical Products 2016; (In Press) doi: 10.17795/jjnpp-40069
|
| 16 |
Shailendra Kapoor. Lubiprostone: Clinical applications beyond constipation. World Journal of Gastroenterology 2009; 15(9): 1147-1147 doi: 10.3748/wjg.15.1147
|
| 17 |
T.B. Lima, O.N. Silva, J.T.A. Oliveira, I.M. Vasconcelos, F.B. Scalabrin, T.L. Rocha, M.F. Grossi-de-Sá, L.P. Silva, R.V. Guadagnin, B.F. Quirino, C.F.S. Castro, E. Leonardecz, O.L. Franco. Identification of E. dysenterica laxative peptide: A novel strategy in the treatment of chronic constipation and irritable bowel syndrome. Peptides 2010; 31(8): 1426 doi: 10.1016/j.peptides.2010.05.003
|
| 18 |
Amber M. Johnson, Radhey S. Kaushik, Philip R. Hardwidge. Disruption of transepithelial resistance by enterotoxigenic Escherichia coli. Veterinary Microbiology 2010; 141(1-2): 115 doi: 10.1016/j.vetmic.2009.08.020
|
| 19 |
Emanuel Raschi, Fabrizio De Ponti. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opinion on Drug Metabolism & Toxicology 2014; 10(2): 293 doi: 10.1517/17425255.2013.876410
|
| 20 |
Sandi Raehtz, Billy M. Hargis, Vivek A. Kuttappan, Rifat Pamukcu, Lisa R. Bielke, Laura R. McCabe. High Molecular Weight Polymer Promotes Bone Health and Prevents Bone Loss Under Salmonella Challenge in Broiler Chickens. Frontiers in Physiology 2018; 9 doi: 10.3389/fphys.2018.00384
|
| 21 |
Katherine R. Henry, Seakwoo Lee, Douglas Walker, Pamela L. Zeitlin. Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells. Physiological Reports 2015; 3(1): e12264 doi: 10.14814/phy2.12264
|